NOVARTIS (SINGAPORE) PTE LTD

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at See our community guidelines:

Our mission is to discover, develop, and successfully market innovative products that improve human health and well-being. We aim to alleviate suffering and enhance the quality of life by providing cutting-edge solutions for disease prevention and treatment.

At Novartis, our mission is to discover new ways to improve and extend people's lives. We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. At Novartis, we focus on five key cancer areas where we have identified patient needs and promise within our portfolio - breast cancer, lung cancer, melanoma, kidney cancer and hematology. As a leader in oncology, Novartis offers a portfolio treating more than 25 conditions worldwide and approximately 30 compounds in development. We are passionate about what we do and the impact we have on patients and societies. We are Novartis, and we are reimagining medicine. See our community guidelines:

At Novartis, we partner with bio pharmaceutical companies to bring high-quality medicines to patients globally. We strive to serve as the manufacturing partner of choice by solving our clients’ manufacturing challenges leveraging the experience of our people and state-of-the-art facilities. This LinkedIn page adopts the guidance of Novartis privacy policy ( and Novartis LinkedIn community guidelines (

At Novartis, we are reimagining medicine to improve and extend people's lives. As a leading global medicines company, we leverage innovative science and digital technologies to develop transformative treatments in areas of great medical need. With a strong focus on research and development, we consistently rank among the world's top investors in this field. Our products reach nearly 1 billion people globally, and we are committed to expanding access to our latest treatments. With a diverse workforce of over 125,000 people from over 140 nationalities, we are proud to have a presence in Singapore since 1986 and employ around 1,000 associates across our divisions.

Sandoz Pharmaceuticals GmbH is a pharmaceuticals company based out of 11 Raiffeisenstraße, Holzkirchen, Germany.

Sandoz is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz annually, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. Read our community engagement guidelines:

Our people With more than 6,000 scientists, physicians and business professionals around the world, we have an open, entrepreneurial and innovative culture that encourages collaboration as we work to push the boundaries of science to change the practice of medicine. NIBR focuses on the following disease areas: •tAutoimmunity, Transplantation, and Inflammatory Disease •tCardiovascular & Metabolic Diseases •tImmuno-oncology •tInfectious Diseases •tMusculoskeletal Diseases •tNeuroscience •tOncology •tOphthalmology •tRespiratory Diseases NIBR has built expertise around several key technology competencies. Each competency combines automation and robotics, computational science, biology and irreplaceable drug discovery knowledge. By building expertise around key technologies, it can be more effectively applied across diseases that share similar mechanisms. •tAnalytical Sciences •tBiologics •tBiomarker Development •tChemistry •tDevelopmental and Molecular Pathways •tDrug Metabolism & Pharmacokinetics •tGenomics Institute of the Novartis Research Foundation › Developing advanced technologies, ranging from cellular genomics and proteomics to combinatorial chemistry and structural biology •tImaging •tMetabolism and Pharmacokinetics •tPreclinical Safety •tProteomic Chemistry •tTranslational Medicine NIBR has locations in: •tBasel, Switzerland •tCambridge, MA •tEast Hanover, NJ •tEmeryville, CA (SF Bay Area) •tSan Diego, CA •tShanghai, China Thank you for taking an interest in the NIBR LinkedIn page. Please read Novartis' LinkedIn community guidelines: